Persistence with oral contraceptive pills versus metformin in women with polycystic ovary syndrome

Journal of Women's Health

Volumn 21, Issue 6, 2012, Pages 690-694

  Karjane, Nicole W ^a   Cheang, Kai I ^b   Mandolesi, Gabriela A ^c   Stovall, Dale W ^d  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c Obstetrical and Gynecological Associates   (United States)

^d UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METFORMIN; ORAL CONTRACEPTIVE AGENT;

ADULT; AMENORRHEA; ANTHROPOMETRIC PARAMETERS; ARTICLE; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERANDROGENISM; MAJOR CLINICAL STUDY; MEDICAL HISTORY; OLIGOMENORRHEA; OVARY POLYCYSTIC DISEASE; PATIENT COMPLIANCE; PREGNANCY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADULT; ANTHROPOMETRY; BODY MASS INDEX; CONTRACEPTIVES, ORAL, COMBINED; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; PILOT PROJECTS; POLYCYSTIC OVARY SYNDROME; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SOCIOECONOMIC FACTORS; URBAN POPULATION;

EID: 84862211470     PISSN: 15409996     EISSN: 1931843X     Source Type: Journal    
DOI: 10.1089/jwh.2011.3116     Document Type: Article

References (28)

1. American College of Obstetricians and Gynecologists Committee on Practice Bulletins Gynecology. ACOG practice bulletin No. 108: Polycystic ovary syndrome. Obstet Gynecol 2009;114:936-949.
2. Castelo-Branco C, Steinvarcel F, Osorio A, Ros C, Balasch J. Atherogenic metabolic profile in PCOS patients: Role of obesity and hyperandrogenism. Gynecol Endocrinol 2010; 26:736-742.
3. Karaer A, Cavkaytar S, Mert I, Buyukkagnici U, Batioglu S. Cardiovascular risk factors in polycystic ovary syndrome. J Obstet Gynaecol 2010;30:387-392.
4. Lambrinoudaki I. Cardiovascular risk in postmenopausal women with the polycystic ovary syndrome. Maturitas 2011; 68:13-16.
5. Teede H, Deeks A, Moran L. Polycystic ovary syndrome: A complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med 2010;8:41.
6. Tomlinson J, Millward A, Stenhouse E, Pinkney J. Type 2 diabetes and cardiovascular disease in polycystic ovary syndrome: What are the risks and can they be reduced? Diabet Med 2010;27:498-515.
7. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:487-497. (Pubitemid 41127293)
8. Abughosh SM, Kogut SJ, Andrade SE, Larrat P, Gurwitz JH. Persistence with lipid-lowering therapy: Influence of the type of lipid-lowering agent and drug benefit plan option in elderly patients. J Manag Care Pharm 2004;10:404-411.
9. Bautista LE. Predictors of persistence with antihypertensive therapy: Results from the NHANES. Am J Hypertens 2008; 21:183-188. (Pubitemid 351231565)
10. Boccuzzi SJ, Wogen J, Fox J, Sung JC, Shah AB, Kim J. Utilization of oral hypoglycemic agents in a drug-insured U.S. population. Diabetes Care 2001;24:1411-1415. (Pubitemid 33716429)
11. El-Serag HB, Fitzgerald S, Richardson P. The extent and determinants of prescribing and adherence with acidreducing medications: A national claims database study. Am J Gastroenterol 2009;104:2161-2167.
12. Esposito D, Wahl P, Daniel G, Stoto MA, Erder MH, Croghan TW. Results of a retrospective claims database analysis of differences in antidepressant treatment persistence associated with escitalopram and other selective serotonin reuptake inhibitors in the United States. Clin Ther 2009;31:644-656.
13. Kane SV, Brixner D, Rubin DT, Sewitch MJ. The challenge of compliance and persistence: Focus on ulcerative colitis. J Manag Care Pharm 2008;14:s2 12.
14. Moghetti P, Castello R, Negri C, et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: A randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab 2000;85:139-146. (Pubitemid 32268804)
15. Strack T. Metformin: A review. Drugs Today (Barc) 2008; 44:303-314. (Pubitemid 351897263)
16. Essah PA, Apridonidze T, Iuorno MJ, Nestler JE. Effects of short-term and long-term metformin treatment on menstrual cyclicity in women with polycystic ovary syndrome. Fertil Steril 2006;86:230-232. (Pubitemid 43962958)
17. Rosenberg MJ, Burnhill MS, Waugh MS, Grimes DA, Hillard PJ. Compliance and oral contraceptives: A review. Contraception 1995;52:137-141.
18. Cramer JA. Compliance with contraceptives and other treatments. Obstet Gynecol 1996;88:4S-12S. (Pubitemid 26293262)
19. Nelson AL, Westhoff C, Schnare SM. Real-world patterns of prescription refills for branded hormonal contraceptives: A reflection of contraceptive discontinuation. Obstet Gynecol 2008;112:782-787.
20. Shaya FT, El Khoury AC, Mullins CD, et al. Drug therapy persistence and stroke recurrence. Am J Manag Care 2006; 12:313-319.
21. Shaya FT, Gu A, Yan X. Effect of persistence with drug therapy on the risk of myocardial re-infarction. P T 2008; 33:288-295.
22. Shenolikar RA, Balkrishnan R, Camacho FT, Whitmire JT, Anderson RT. Comparison of medication adherence and associated health care costs after introduction of pioglitazone treatment in African Americans versus all other races in patients with type 2 diabetes mellitus: A retrospective data analysis. Clin Ther 2006;28:1199-1207. (Pubitemid 44376810)
23. Avorn J, Monette J, Lacour A, et al. Persistence of use of lipid-lowering medications: A cross-national study. JAMA 1998;279:1458-1462. (Pubitemid 28228203)
24. Sawada N, Uchida H, Suzuki T, et al. Persistence and compliance to antidepressant treatment in patients with depression: A chart review. BMC Psychiatry 2009;9:38.
25. Shrank WH, Hoang T, Ettner SL, et al. The implications of choice: Prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions. Arch Intern Med 2006;166:332-337. (Pubitemid 43244321)
26. Zhang D, Carlson AM, Gleason PP, et al. Relationship of the magnitude of member cost-share and medication persistence with newly initiated renin angiotensin system blockers. J Manag Care Pharm 2007;13:664-676. (Pubitemid 350065235)
27. Hasford J, Schroder-Bernhardi D, Rottenkolber M, Kostev K, Dietlein G. Persistence with antihypertensive treatments: Results of a 3-year follow-up cohort study. Eur J Clin Pharmacol 2007;63:1055-1061. (Pubitemid 47561800)
28. Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X. Interventions for enhancing medication adherence. Cochrane Database Syst Rev 2008;16:CD000011.